CTXR - CIK 0001506251
The table below shows Citius Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q4 2024 | Q4 2023 | Q4 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$13.01M | -$4.73M | -$6.14M | -$4.82M | -$4.65M | -$9.56M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$4.40M | - | - | - | - | - |
| Dividends paid | - | - | - | - | - | - |
Citius Pharmaceuticals, Inc. reported operating cash flow of -$26.55M for fiscal year 2025. That is up 5.8% from -$28.20M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$5.90M (FY 2016) to -$26.55M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $20.88M | $2.57M | - | - | - | $500.00 |